GLP-1 receptor agonists, including semaglutide and tirzepatide, have been the subject of one of the largest peptide clinical trial programmes published to date. A consistent observation in this literature is that a substantial proportion of trial-reported weight change is attributable to lean body mass rather than adipose tissue alone. This article summarises what the published research reports and the mechanisms researchers have proposed to explain it. It is a research summary only and does not contain instructions, protocols or advice for anyone using these or any other medicines.
What Published Trials Report
Body composition substudies of the STEP and SURMOUNT trial programmes have reported lean mass change as a measurable proportion of total weight change. Wilding et al. (NEJM, 2021) reported that approximately 39% of total weight lost in the semaglutide 2.4 mg arm of STEP 1 was attributable to lean body mass on DEXA imaging. Reported proportions vary across trials, compounds, dose levels and measurement methods.
These figures describe patient cohorts in registered clinical trials of licensed medicines. They are reported here as published literature, not as predictions about any individual or any other compound, and not as guidance about research reference material.
Mechanistic Hypotheses in the Literature
Researchers have proposed several mechanisms to explain reported lean mass change in GLP-1 receptor agonist trials:
- Caloric deficit: Any sustained caloric deficit is associated with lean mass loss, independent of the mechanism driving it.
- Reduced protein intake: Broad appetite suppression observed in trial participants may reduce absolute protein intake and protein density at meals.
- Rate of weight loss: Published nutrition literature reports that faster rates of weight loss are associated with higher lean mass losses as a proportion of total change.
- Anabolic resistance: Some authors have proposed that incretin signalling itself may influence skeletal muscle protein turnover, though this remains an open research question.
Investigational Compounds in Clinical Research
Bimagrumab (Anti-ActRII Antibody)
Bimagrumab is a monoclonal antibody that blocks activin type II receptors, inhibiting myostatin signalling in skeletal muscle. Heymsfield et al. (2024) reported a Phase II study in which bimagrumab combined with semaglutide produced body composition changes with a higher proportion of fat mass loss than semaglutide alone. The compound remains investigational and is not licensed for human use.
Apitegromab
A selective anti-myostatin antibody currently being studied in clinical trials for spinal muscular atrophy. Its application in metabolic body composition research is the subject of ongoing investigation.
Body Composition Measurement in Research
Trials that report lean mass typically rely on dual-energy X-ray absorptiometry (DEXA) or magnetic resonance imaging. Bioelectrical impedance and tape measurements are less precise and are not generally used as primary endpoints in registration trials.
Related Research Summaries
- Semaglutide regulatory status and published research: see semaglutide research summary
- Reported adverse events with GLP-1 receptor agonists: see GLP-1 adverse event summary
- Tirzepatide vs semaglutide research comparison: comparison page
Key References
- Wilding, J.P.H. et al. (2021). "Once-weekly semaglutide in adults with overweight or obesity." NEJM, 384, 989-1002.
- Heymsfield, S.B. et al. (2024). "Effect of bimagrumab vs placebo on body fat mass among adults with overweight or obesity." Published clinical trial data.
- Cava, E. et al. (2017). "Preserving healthy muscle during weight loss." Advances in Nutrition, 8(3), 511-519.